Shai Mulinari
11 – 20 of 101
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
“Black race”, “Schwarze Hautfarbe”, “Origine africaine”, or “Etnia nera”? The absent presence of race in European pharmaceutical regulation
- Contribution to journal › Article
-
Mark
Aligning digital biomarker definitions in psychiatry with the National Institute of Mental Health Research Domain Criteria framework
- Contribution to journal › Article
-
Mark
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
- Contribution to journal › Article
-
Mark
Drug company methodologies used for reporting in the UK pharmaceutical industry payment transparency database between 2015 and 2019 : A content analysis
- Contribution to journal › Article
-
Mark
Delays in dealing with complaints against drug companies are growing, BMJ finds
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Läkares jäv bör redovisas i media
(2024) In Dagens Media
- Contribution to specialist publication or newspaper › Newspaper article
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
- Contribution to journal › Article
-
Mark
Broken beyond repair: self regulation of industry payments to clinicians and hospitals
- Contribution to journal › Debate/Note/Editorial
- 2023
-
Mark
Pharmaceutical industry payments to NHS trusts in England : A four-year analysis of the Disclosure UK database
- Contribution to journal › Article
-
Mark
Authors’ reply to Fell
- Contribution to journal › Letter